Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × Thalassemia × fludarabine × Clear all

Phase

Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 7 Multiple Myeloma 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Lymphoma, Non-Hodgkin 4 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Leukemia 4 Hodgkin Disease 4 Hematologic Neoplasms 4 Lymphoma, Mantle-Cell 3 Lymphoma, Follicular 3 Anemia, Refractory, with Excess of Blasts 3 Recurrence 2 Primary Myelofibrosis 2 Myelodysplastic Syndromes 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma, B-Cell 2 Leukemia, Prolymphocytic 2 Burkitt Lymphoma 2 Thalassemia 1 Skin Neoplasms 1 Peritoneal Tumor 1 Pancreatic Neoplasms 1 Neoplasms, Plasma Cell 1 Mesothelin-positive Advanced Malignant Solid Tumors 1 Melanoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Leukemia, Plasma Cell 1 Leukemia, B-Cell 1

Interventions

fludarabine phosphate 1 fludarabine 1 Mesna 1 Cyclophosphamide 1 Busulfan 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00578292 2020-05-01

THALLO

Baylor College of Medicine

Phase NA Terminated

10 enrolled 15 charts

Lymphoma, Follicular, Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡